Artificial Intelligence

X-Humanoid Introduces Tien Kung 3.0 as Deployment Challenges Persist in Humanoid Robotics

A closer look at the tech, AI, and open ecosystem behind Tien Kung 3.0’s real-world push

Updated

March 17, 2026 1:02 AM

Humanoid robots working in a warehouse. PHOTO: ADOBE STOCK

Humanoid robotics has advanced quickly in recent years. Machines can now walk, balance, and interact with their surroundings in ways that once seemed out of reach. Yet most deployments remain limited. Many robots perform well in controlled settings but struggle in real-world environments. Integration is often complex, hardware interfaces are closed, software tools are fragmented, and scaling across industries remains difficult.

Against this backdrop, X-Humanoid has introduced its latest general-purpose platform, Embodied Tien Kung 3.0. The company positions it not simply as another humanoid robot, but as a system designed to address the practical barriers that have slowed adoption, with a focus on openness and usability.

At the hardware level, Embodied Tien Kung 3.0 is built for mobility, strength, and stability. It is equipped with high-torque integrated joints that provide strong limb force for high-load applications. The company says it is the first full-size humanoid robot to achieve whole-body, high-dynamic motion control integrated with tactile interaction. In practice, this means the robot is designed to maintain balance and execute dynamic movements even in uneven or cluttered environments. It can clear one-meter obstacles, perform consecutive high-dynamic maneuvers, and carry out actions such as kneeling, bending, and turning with coordinated whole-body control.

Precision is also a focus. Through multi-degree-of-freedom limb coordination and calibrated joint linkage, the system is designed to achieve millimeter-level operational accuracy. This level of control is intended to support industrial-grade tasks that require consistent performance and minimal error across changing conditions.

But hardware is only part of the equation. The company pairs the robot with its proprietary Wise KaiWu general-purpose embodied AI platform. This system supports perception, reasoning, and real-time control through what the company describes as a coordinated “brain–cerebellum” architecture. It establishes a continuous perception–decision–execution loop, allowing the robot to operate with greater autonomy and reduced reliance on remote control.

For higher-level cognition, Wise KaiWu incorporates components such as a world model and vision-language models (VLM) to interpret visual scenes, understand language instructions, and break complex objectives into structured steps. For real-time execution, a vision-language-action (VLA) model and full autonomous navigation system manage obstacle avoidance and precise motion under variable conditions. The platform also supports multi-agent collaboration, enabling cross-platform compatibility, asynchronous task coordination, and centralized scheduling across multiple robots.

A central part of the platform is openness. The company states that the system is designed to address compatibility and adaptation challenges across both development and deployment layers. On the hardware side, Embodied Tien Kung 3.0 includes multiple expansion interfaces that support different end-effectors and tools, allowing faster adaptation to industrial manufacturing, specialized operations, and commercial service scenarios. On the software side, the Wise KaiWu ecosystem provides documentation, toolchains, and a low-code development environment. It supports widely adopted communication standards, including ROS2, MQTT, and TCP/IP, enabling partners to customize applications without rebuilding core systems.

The company also highlights its open-source approach. X-Humanoid has open-sourced key components from the Embodied Tien Kung and Wise KaiWu platforms, including the robot body architecture, motion control framework, world model, embodied VLM and cross-ontology VLA models, training toolchains, the RoboMIND dataset, and the ArtVIP simulation asset library. By opening access to these elements, the company aims to reduce development costs, lower technical barriers, and encourage broader participation from researchers, universities, and enterprises.

Embodied Tien Kung 3.0 enters a market where technical progress is visible but large-scale adoption remains uneven. The gap is not only about movement or strength. It is about integration, interoperability, and the ability to operate reliably and autonomously in everyday industrial and commercial settings. If platforms can reduce fragmentation and simplify deployment, humanoid robots may move beyond demonstrations and into sustained commercial use.

In that sense, the significance of Embodied Tien Kung 3.0 lies less in isolated technical claims and more in how its high-dynamic hardware, embodied AI system, open interfaces, and collaborative architecture are structured to work together. Whether that integrated approach can close the deployment gap will shape how quickly humanoid robotics becomes part of real-world operations.

Keep Reading

Hong Kong

Hong Kong AI Biotech Startup METiS TechBio Draws Major Investor Demand in IPO

METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body

Updated

May 14, 2026 3:02 PM

HIV-1 virus particles, coloured red. PHOTO: UNSPLASH

Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.

The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.

Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.

The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.

That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.

METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.

The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.

One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.

Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.

METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.

The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.

Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."

The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.

For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.